Methods	Eight-week, double-blind, randomised, multicentre study.
Participants	Outpatients meeting DSM-IV criteria for Major Depressive Disorder and having a minimum score of 22 on Montgomery-Asberg Depression Rating Scale. Age range: 18-80 years.
Interventions	Escitalopram: 138 participants. Bupropion XR: 147 participants. Escitalopram dose: 4 mg/day. Bupropion XR dose: 150 mg.
Outcomes	Primary Outcome: Change from baseline to week 8 in Montgomery-Asberg Depression Rating Scale. Secondary Outcome: Hamilton Depression Rating Scale - 24 item
Notes	Only unpublished data. This study was funded by escitalopram manufacturer
Risk of bias
Item	Authors’ judgement	Description
Adequate sequence generation?	Yes	Quote: “randomized”. Probably done
Allocation concealment?	Unclear	No information provided.
Blinding? All outcomes	Unclear	Quote: “double-blind”.
Incomplete outcome data addressed? All outcomes	Yes	Quote: ITT analysis (“all patients with at least one post-baseline assessment of MADRS”)
Free of selective reporting?	Unclear	No information provided.
Free of other bias?	Unclear	No information provided.